What treatment options are recommended for a patient with relapsed gamma‑delta hepatosplenic T‑cell lymphoma after allogeneic stem‑cell transplantation, who has active hemophagocytic lymphohistiocytosis and CD38‑positive disease refractory to daratumumab?

Treatment Options for Relapsed Gamma-Delta HSTCL Post-Allo with HLH

Given daratumumab failure and active HLH in this post-allogeneic transplant relapse setting, prioritize alemtuzumab as a bridge to donor lymphocyte infusion (DLI) or second allogeneic transplant with enhanced myeloablative conditioning, while simultaneously treating HLH with etoposide-based therapy or ruxolitinib.

Immediate Dual-Track Approach Required

This clinical scenario demands addressing two life-threatening conditions simultaneously:

1. HLH Management (Priority for Immediate Mortality Risk)

Active HLH requires urgent intervention as it carries immediate mortality risk:

• Alemtuzumab is the most evidence-supported agent for refractory HLH as a bridge to definitive therapy 1, 2

  • Targets CD52-positive lymphocytes and can control both HLH and residual lymphoma cells
  • Well-documented success in achieving remission in atypical HLH refractory to standard therapy 1
  • In relapsed/refractory HLH, alemtuzumab achieved partial response rates of 14-77% and successfully bridged 44.8-77% of patients to HSCT 2

• Alternative HLH-directed agents if alemtuzumab unavailable:

  • Ruxolitinib (JAK1/2 inhibitor) - increasingly used for refractory HLH with favorable toxicity profile 2
  • Emapalumab (anti-IFN-γ antibody) - though primarily pediatric data 2
  • DEP regimen (dexamethasone, etoposide, pegaspargase) if not previously used 2

2. Lymphoma-Directed Therapy

For the underlying HSTCL, the evidence strongly supports:

Salvage transplant approach with enhanced conditioning is the only potentially curative option 3, 4:

• Enhanced myeloablative preconditioning (TBI/splenic irradiation/GEM/CLAG/ATG) achieved disease-free survival in refractory HSTCL cases 3
• Both auto-HCT and allo-HCT show similar outcomes (median OS 78.5 months, PFS 54 months) in transplant-eligible patients 4
• Since this patient already relapsed post-allo, consider:
  • DLI (donor lymphocyte infusion) if sufficient disease control achieved with bridging therapy
  • Second allogeneic transplant with different donor or enhanced conditioning if DLI insufficient 3

Bridging chemotherapy options per NCCN guidelines 5:

• Alemtuzumab (dual purpose: treats HLH and CD52+ lymphoma cells) - most logical choice here
• GemOx (gemcitabine/oxaliplatin) - reasonable tolerability
• ICE or DHAP regimens - if performance status permits
• Single-agent options if too ill for combination therapy:
  • Gemcitabine
  • Bendamustine
  • Pralatrexate (though limited activity in some T-cell subtypes)

Why Daratumumab Failed and What This Means

The FDA label confirms daratumumab targets CD38 on hematopoietic cells 6, and while CD38 is expressed on many hematologic malignancies, daratumumab-refractory disease in T-cell lymphoma suggests either:

• Inadequate CD38 expression density despite flow cytometry positivity
• Resistance mechanisms (NK cell depletion by daratumumab itself may impair ADCC) 6
• T-cell lymphomas are not the primary indication for daratumumab (approved for myeloma)

CD38-directed CAR-T showed promise in relapsed AML post-transplant 7, but this is investigational and not standard for HSTCL.

Critical Pitfalls to Avoid

1. Do not delay HLH treatment - HLH carries immediate mortality risk independent of lymphoma burden
2. Do not use standard CHOP-based regimens - HSTCL is notoriously chemoresistant to anthracyclines 8, 9
3. Do not attempt transplant with active HLH - mortality is significantly higher with active disease pre-transplant 2
4. Monitor for CMV reactivation with alemtuzumab use 5
5. Recognize that post-transplant HSTCL has especially poor outcomes without aggressive intervention 8

Practical Algorithm

1. Week 1-2: Initiate alemtuzumab (addresses both HLH and lymphoma) with CMV monitoring
2. Week 2-4: Assess HLH response (ferritin, fibrinogen, cytopenia improvement) and disease burden
3. Week 4-6: If HLH controlled and disease responding:
   • Proceed to DLI if minimal residual disease
   • Proceed to second allo-HCT with enhanced conditioning if significant disease burden 3
4. If alemtuzumab insufficient: Add ruxolitinib for HLH control and consider GemOx for lymphoma cytoreduction

Prognosis Context

HSTCL in children/adolescents has <15% 5-year OS even with intensive therapy 9. Post-transplant relapse is particularly dire 8. However, the case series using enhanced myeloablative conditioning achieved sustained disease-free survival 3, and the multicenter HCT study showed median OS of 78.5 months for transplanted patients 4, making aggressive pursuit of second transplant reasonable if bridging therapy achieves disease control.